BioCardia Receives FDA Market Clearance for Morph DNA Products
BioCardia, Inc. [Nasdaq: BCDA] has announced that the Food and Drug Administration (FDA) has granted market clearance for its Morph DNA Steerable Introducer product line. This important regulatory approval opens up a new avenue for the introduction of medical instruments into various vascular systems.
Introducing the Morph DNA Steerable Introducer
The Morph DNA Steerable Introducer family is specifically designed to assist in the introduction of vital medical devices, such as balloon dilatation catheters and guidewires, into both peripheral and coronary vascular systems. The recent clearance includes sixteen different products, which vary in lengths of 30, 45, 71, and 90 centimeters, as well as in French introducer sheath equivalent diameters of 5, 6, 7, and 8.
Applications in Cardiovascular Health
These cutting-edge devices are expected to support a broad range of clinical applications in interventional cardiology, interventional radiology, cardiac electrophysiology, and vascular surgery. They are poised to significantly enhance both common and advanced procedures performed in medical facilities, including those required for peripheral vascular interventions, renal denervation to manage hypertension, endovascular aortic repairs, carotid artery stenting, and procedures aimed at addressing perivalvular leaks.
Importance of the FDA Clearance
Peter Altman, PhD, President and CEO of BioCardia, expressed excitement about the FDA clearance, highlighting that their previous single-diameter Morph product has successfully supported approximately 12,000 procedures across various clinical indications. The company is eager to introduce the advanced Morph DNA products to healthcare professionals, offering substantial benefits to both physicians and patients.
Significant Impact on Procedure Efficiency
BioCardia estimates that over a million procedures performed annually could benefit from the Morph DNA products, which are expected to have a starting list price of $1,000. This presents a genuine opportunity to significantly enhance procedural efficiency and improve patient outcomes.
Innovative Features of Morph DNA
The Morph DNA steerable introducer is designed to provide improved control during complex procedures. With features like bidirectional steering, ergonomic actuation, and an adjustable brake for fine-tuning control, these devices are crafted to tackle challenges commonly faced in the operating room. Notably, the tensioning elements integrated into the catheters allow for superior navigational capabilities, thereby minimizing potential complications such as unexpected catheter movement.
Emphasis on Advanced Interventional Procedures
Originally developed to improve navigation within the left ventricle during specialized cardiovascular therapies, the Morph DNA product family showcases BioCardia's dedication to innovation in medical devices. The ergonomic and functional design aims to provide physicians with better access, control, and overall performance in delivering therapies to patients.
About BioCardia
BioCardia, Inc. is recognized as a global leader in developing cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases. Known for its innovative CardiAMP® and CardiALLO™ cell therapies, the company is advancing three clinical stage product candidates within its biotherapeutic platforms. Alongside the Helix™ biotherapeutic delivery system and the Morph® vascular navigation solutions, BioCardia continues to push the limits of what is achievable in therapeutic interventions.
Frequently Asked Questions
What is the Morph DNA Steerable Introducer?
The Morph DNA Steerable Introducer is a series of medical devices designed to facilitate the introduction of various therapeutic instruments into peripheral and coronary vascular systems.
What clinical applications will benefit from these devices?
The devices will support procedures in interventional cardiology, including renal denervation, aortic repairs, and stenting.
How many products are included in the approved Morph DNA family?
There are sixteen products in the Morph DNA Steerable Introducer family, covering a range of lengths and diameters.
What advantages do the Morph DNA devices provide?
These devices offer enhanced control, reduced procedure times, and improved navigation capabilities for complex medical interventions.
How does BioCardia perform in the market?
BioCardia is a significant player in the biotherapeutics sector, consistently advancing innovative solutions aimed at improving patient outcomes in cardiovascular and pulmonary health.
